Accuray (ARAY) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Accuray (ARAY) over the past year, gaining 23.2% versus a loss of 85.6%. Accuray is the larger company by market cap ($28.8 million vs $21.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | PLRZ |
|---|---|---|
| Share price | $0.2414 | $8.87 |
| Market cap | $28.83M | $21.54M |
| 1-day change | -4.74% | -3.06% |
| YTD return | -70.56% | +4.48% |
| 1-year return | -85.63% | +23.19% |
| 5-year return | -93.86% | — |
| EPS (TTM) | $-0.40 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.10 | $18.20 |
| 52-week low | $0.22 | $2.88 |
| Distance from 52-week high | -88.50% | -51.26% |
| Analyst consensus | none | — |
| Average volume | 7.19M | 60.55K |
| Shares outstanding | 119.44M | 2.43M |
| Employees | 809 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed ARAY by 108.8 percentage points over the past year.
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Healthcare · Medical Devices · 809 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Healthcare · Biotechnology · 2 employees
ARAY vs PLRZ FAQ
Which is bigger, Accuray or Polyrizon?
Accuray (ARAY) is larger, with a market capitalization of $28.83M compared with $21.54M for Polyrizon (PLRZ).
Which stock has performed better over the past year, ARAY or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -85.63% for ARAY (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and Polyrizon in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Accuray and Biotechnology for Polyrizon.